Galecto to Present at Upcoming Investor Conferences

Rhea-AI Summary

Galecto, Inc. (NASDAQ: GLTO), a biotechnology firm focused on fibrosis and cancer treatments, announces participation in two key healthcare conferences. The management team will present virtually at the Credit Suisse Healthcare Conference on November 10, 2021, at 8:00 AM ET, and in-person at the Jefferies London Healthcare Conference on November 16, 2021, at 8:30 AM ET. Attendees can expect insights into Galecto’s ongoing clinical trials, including treatments for idiopathic pulmonary fibrosis and myelofibrosis. Live audio webcasts will be available on their investor website.

BOSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Galecto’s management team will be presenting virtually at the Credit Suisse Healthcare Conference and in-person at the Jefferies London Healthcare Conference. Galecto’s management team will be available for 1x1 meetings at both of these conferences. Details for the presentations are below:

Credit Suisse Healthcare Conference
Date:	November 10, 2021
Time:	8:00am ET
Jefferies London Healthcare Conference
Date:	November 16, 2021
Time:	8:30am ET

A live audio webcast will be available on the "News & Events" section of Galecto’s Investor website at https://ir.galecto.com/news-and-events/events. A replay of each presentation will be available on this same website following the event.

About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a phase 1b/2a trial in liver cirrhosis and expected to be evaluated in a phase 2 trial for the treatment of NSCLC in combination with an anti-PD1/-L1 product.

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.

For more information, contact:

Galecto, Inc.
Hans Schambye, CEO Jon Freve, CFO
+45 70 70 52 10
Investor Relations US	Investor/Media Relations EU
Ashley R. Robinson arr@lifesciadvisors.com	Sandya von der Weid svonderweid@lifesciadvisors.com
+1 617 430 7577	+41 78 680 0538

FAQ

What dates will Galecto present at the Credit Suisse Healthcare Conference?

Galecto will present at the Credit Suisse Healthcare Conference on November 10, 2021.

What time is Galecto's presentation at the Jefferies London Healthcare Conference?

Galecto's presentation at the Jefferies London Healthcare Conference is scheduled for 8:30 AM ET on November 16, 2021.

Where can I find the live webcast for Galecto's conference presentations?

The live audio webcast for Galecto's presentations can be found in the 'News & Events' section of their investor website.

What is Galecto's focus in clinical development?

Galecto is focused on developing novel treatments for fibrosis and cancer, with various Phase 2 clinical programs.

What specific treatments is Galecto developing?

Galecto is developing treatments such as an inhaled galectin-3 modulator for idiopathic pulmonary fibrosis and an orally active LOXL2 inhibitor for myelofibrosis.